Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2023 Jan 16

PMID 36645796

Authors

Peter L Anderson

Mark A Marzinke

David V Glidden

Affiliations

Soon will be listed here.

Abstract

Using intraerythrocytic tenofovir-diphosphate data from the emtricitabine/tenofovir disoproxil fumarate arms of HIV Prevention Trials Network (HPTN) 083 (men) and HPTN 084 (women), approximately 99% efficacy was achieved at a lower adherence threshold in HPTN 083 (≥2 doses/week) compared with HPTN 084 (daily), suggesting higher adherence is necessary for women vs men.

Citing Articles

High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort.

Gati Mirembe B, Donnell D, Krows M, Zwane Z, Bukusi E, Panchia R J Int AIDS Soc. 2024; 27(12):e26389.

PMID: 39653676 PMC: 11628190. DOI: 10.1002/jia2.26389.

Adherence measurement considerations for oral antiretroviral medications.

Coppinger C, Anderson P J Int AIDS Soc. 2024; 27(12):e26397.

PMID: 39587904 PMC: 11589385. DOI: 10.1002/jia2.26397.

Updated guidelines on HIV post-exposure prophylaxis: continued efforts towards increased accessibility.

Allan-Blitz L, Mayer K J Int AIDS Soc. 2024; 27(11):e26393.

PMID: 39576221 PMC: 11583823. DOI: 10.1002/jia2.26393.

Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subcutaneous implant.

Kim H, Zhang L, Hendrix C, Haberer J, von Kleist M CPT Pharmacometrics Syst Pharmacol. 2024; 13(10):1693-1706.

PMID: 39164932 PMC: 11494919. DOI: 10.1002/psp4.13212.

Establishing adherence-concentration-efficacy thresholds of TDF-FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF-FTC Benchmark Study.

Wu L, Saina M, Brown C, Chege D, Donnell D, Glidden D Front Reprod Health. 2024; 6:1325257.

PMID: 38860025 PMC: 11163076. DOI: 10.3389/frph.2024.1325257.

References

Cottrell M, Yang K, Prince H, Sykes C, White N, Malone S . A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis. 2016; 214(1):55-64. PMC: 4907409. DOI: 10.1093/infdis/jiw077. View

Eshleman S, Fogel J, Piwowar-Manning E, Chau G, Cummings V, Agyei Y . Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022; 225(10):1741-1749. PMC: 9113509. DOI: 10.1093/infdis/jiab576. View

Sadik Shaik J, Weld E, Edick S, Fuchs E, Riddler S, Marzinke M . Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis. Br J Clin Pharmacol. 2021; 88(4):1667-1678. PMC: 9290068. DOI: 10.1111/bcp.14980. View

Patterson K, Prince H, Kraft E, Jenkins A, Shaheen N, Rooney J . Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011; 3(112):112re4. PMC: 3483088. DOI: 10.1126/scitranslmed.3003174. View

Andrews C, Yueh Y, Spreen W, St Bernard L, Boente-Carrera M, Rodriguez K . A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015; 7(270):270ra4. PMC: 4449736. DOI: 10.1126/scitranslmed.3010298. View

Stranix-Chibanda L, Anderson P, Kacanek D, Hosek S, Huang S, Nematadzira T . Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. Clin Infect Dis. 2020; 73(7):e1893-e1900. PMC: 8492211. DOI: 10.1093/cid/ciaa1872. View

Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L . Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021; 385(7):595-608. PMC: 8448593. DOI: 10.1056/NEJMoa2101016. View

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

Delany-Moretlwe S, Hughes J, Bock P, Ouma S, Hunidzarira P, Kalonji D . Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022; 399(10337):1779-1789. PMC: 9077443. DOI: 10.1016/S0140-6736(22)00538-4. View

10.

Andrews C, Spreen W, Mohri H, Moss L, Ford S, Gettie A . Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014; 343(6175):1151-4. PMC: 4308974. DOI: 10.1126/science.1248707. View

11.

Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9):820-9. PMC: 6107918. DOI: 10.1016/S1473-3099(14)70847-3. View

12.

Patel P, Borkowf C, Brooks J, Lasry A, Lansky A, Mermin J . Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014; 28(10):1509-19. PMC: 6195215. DOI: 10.1097/QAD.0000000000000298. View

13.

Baeten J, Donnell D, Mugo N, Ndase P, Thomas K, Campbell J . Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014; 14(11):1055-1064. PMC: 4252589. DOI: 10.1016/S1473-3099(14)70937-5. View

14.

Molina J, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I . On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015; 373(23):2237-46. DOI: 10.1056/NEJMoa1506273. View

15.

Marzinke M, Grinsztejn B, Fogel J, Piwowar-Manning E, Li M, Weng L . Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect Dis. 2021; 224(9):1581-1592. PMC: 8599849. DOI: 10.1093/infdis/jiab152. View